Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death

被引:185
作者
Apple, FS
Murakami, MM
Pearce, LA
Herzog, CA
机构
[1] Univ Minnesota, Hennepin Cty Med Ctr, Sch Med, Clin Labs P4,Dept Lab Med & Pathol, Minneapolis, MN 55415 USA
[2] Univ Minnesota, Hennepin Cty Med Ctr, Sch Med, Dept Med, Minneapolis, MN 55415 USA
关键词
D O I
10.1373/clinchem.2004.035741
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: In patients, with end-stage renal disease (ESRD), the ability of single and multiple biomarker monitoring to predict adverse outcomes has not been well established. This study determined the prognostic value of multiple biomarkers for all-cause death over 2 years in 399 ESRD patients. Methods; The risk of all-cause death was determined by use of multiple bionmarkers based on concentrations for a reference population (normal) and cutoffs based on tertile distributions in the ESRD group. Piomarkers studied included N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hsCRP; Dade Behring and Roche assays), and cardiac troponin T (cTnT; Roche) and I (cTnI, Dade Behring and Beckman Coulter assays). Relative risks of death were estimated and survival curves computed. Results:. A total of 101 deaths occurred during 594 patient-years of follow-up. Increased NT-proBNP concentrations were not predictive of death on the basis of the normal cutoffs. However, tertile analysis,of NT-proBNP was significantly predictive of death and had a ROC area under the curve equivalent to or better than any of the other biomarkers. Biomarkers independently predictive of survival were hsCRP (P <0.001, either assay), cTnT (P <0.05), and cTnI (Dade, P <0.05). Two-year mortality rates were 6% (n = 45) with normal hsCRP, cTnI, and cTnT concentrations; 19% (n = 173) with increased hsCRP or cTnT and normal cTnI; 44% (n = 160) with both hsCRP and cTnT increased and normal cTnI; 61% (n = 21) with increased cTnI (Dade) or 47% (n 74) with increased cTnI (Beckman) regardless of hsCRP or cTnT concentrations. Defined by the nor mal cutoffs, increased concentrations of biomarkers were present in various proportions of the 399 patients with ESRD: NT-p.r-oBNP, 99%; hsCRP, 46% (both Roche and Dade assays); cTnT, 85%; cTnI, 19% (Beckman assay) And 5% (Dade, assay). Conclusions: Although mechanisms likely vary for causation, increased plasma fisCRP, cTnT, and cTnI above the cutoffs for our reference (normal) population were all independently predictive of subsequent death in ESRD patients. Tertile- analysis for NT-proBNP also demonstrated prognostic value. (C) 2004,American Association for Clinical Chemistry.
引用
收藏
页码:2279 / 2285
页数:7
相关论文
共 35 条
  • [1] Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
    Alpert, JS
    Antman, E
    Apple, F
    Armstrong, PW
    Bassand, JP
    de Luna, AB
    Beller, G
    Breithardt, G
    Chaitman, BR
    Clemmensen, P
    Falk, E
    Fishbein, MC
    Galvani, M
    Garson, A
    Grines, C
    Hamm, C
    Jaffe, A
    Katus, H
    Kjekshus, J
    Klein, W
    Klootwijk, P
    Lenfant, C
    Levy, D
    Levy, RI
    Luepker, R
    Marcus, F
    Näslund, U
    Ohman, M
    Pahlm, O
    Poole-Wilson, P
    Popp, R
    Alto, P
    Pyörälä, K
    Ravkilde, J
    Rehnquist, N
    Roberts, W
    Roberts, R
    Roelandt, J
    Rydén, L
    Sans, S
    Simoons, ML
    Thygesen, K
    Tunstall-Pedoe, H
    Underwood, R
    Uretsky, BF
    Van de Werf, F
    Voipio-Pulkki, LM
    Wagner, G
    Wallentin, L
    Wijns, W
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) : 959 - 969
  • [2] European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: How to use existing assays clinically and for clinical trials
    Apple, FS
    Wu, AHB
    Jaffe, AS
    [J]. AMERICAN HEART JOURNAL, 2002, 144 (06) : 981 - 986
  • [3] Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease
    Apple, FS
    Murakami, MM
    Pearce, LA
    Herzog, CA
    [J]. CIRCULATION, 2002, 106 (23) : 2941 - 2945
  • [4] End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link?
    Arici, M
    Walls, J
    [J]. KIDNEY INTERNATIONAL, 2001, 59 (02) : 407 - 414
  • [5] Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction
    Aviles, RJ
    Askari, AT
    Lindahl, B
    Wallentin, L
    Jia, G
    Ohman, EM
    Mahaffey, KW
    Newby, LK
    Califf, RM
    Simoons, ML
    Topol, EJ
    Lauer, MS
    Berger, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (26) : 2047 - 2052
  • [6] Management of acute coronary syndromes:: acute coronary syndromes without persistent ST segment elevation -: Recommendations of the Task Force of the European Society of Cardiology
    Bertrand, ME
    Simoons, ML
    Fox, KAA
    Wallentin, LC
    Hamm, CW
    McFadden, E
    De Feyter, PJ
    Specchia, G
    Ruzyllo, W
    [J]. EUROPEAN HEART JOURNAL, 2000, 21 (17) : 1406 - 1432
  • [7] Sudden and cardiac death rates in hemodialysis patients
    Bleyer, AJ
    Russell, GB
    Satko, SG
    [J]. KIDNEY INTERNATIONAL, 1999, 55 (04) : 1553 - 1559
  • [8] ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction
    Braunwald, E
    Antman, EM
    Beasley, JW
    Califf, RM
    Cheitlin, MD
    Hochman, JS
    Jones, RH
    Kereiakes, D
    Kupersmith, J
    Levin, TN
    Pepine, CJ
    Schaeffer, JW
    Smith, EE
    Steward, DE
    Theroux, P
    Gibbons, RJ
    Alpert, JS
    Eagle, KA
    Faxon, DP
    Fuster, V
    Gardner, TJ
    Gregoratos, G
    Russell, RO
    Smith, SC
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) : 970 - 1056
  • [9] Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling
    Cataliotti, A
    Malatino, LS
    Jougasaki, M
    Zoccali, C
    Castellino, P
    Giacone, G
    Bellanuova, I
    Tripepi, R
    Seminara, G
    Parlongo, S
    Stancanelli, B
    Bonanno, G
    Fatuzzo, P
    Rapisarda, F
    Belluardo, P
    Signorelli, SS
    Heublein, DM
    Lainchbury, JG
    Leskinen, HK
    Bailey, KR
    Redfield, MM
    Burnett, JC
    [J]. MAYO CLINIC PROCEEDINGS, 2001, 76 (11) : 1111 - 1119
  • [10] Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis
    Clerico, A
    Caprioli, R
    Del Ry, S
    Giannessi, D
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (01) : 24 - 30